• Senzime’s Q3 2026 loss after financial items narrowed 54% to SEK 12.02 million.
• Net sales rose 14% to SEK 30.1 million, driven by higher sales across all regions.
• Operating expenses fell 15% to SEK 31.04 million.
• A July agreement with Philips Medical Systems covers jointly developed solutions for commercialization through Philips’ global organization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senzime AB published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.